Companies

biote Corp.

BTMD · CIK 0001819253 · operating

$2.09-1.42%Last updated Mar 2, 8:29 PM

Key Statistics

Valuation

Market Cap$100.01M
P/E2.65
Fwd P/E2.52
PEG
P/S0.51
P/B
EV/EBITDA3.95
EV/Rev0.79

Profitability

Gross Margin
Op. Margin16.03%
Net Margin1.60%
ROE-2.98%
ROA2.58%
FCF Margin19.68%

Financial Health

Current Ratio1.32
Debt/Equity-2.12
Free Cash Flow$38.81M
Div. Yield

Growth & Other

Revenue Growth6.38%
EPS Growth-30.77%
Beta1.15
52W High$4.75
52W Low$2.015

About biote Corp.

biote Corp. operates a practice-building platform focused on hormone optimization using bioidentical hormone replacement pellet therapy. The company trains and certifies physicians and nurse practitioners in the Biote Method, providing an end-to-end system designed to help practitioners establish and manage hormone optimization practices. The platform combines practitioner education and certification with software tools that enable practitioners to manage patient care, track inventory, and handle administrative requirements.

The company generates revenue through multiple streams centered on its certified practitioner network. These include licensing fees from the Biote Method platform, practice management and inventory software subscriptions, sales of hormone replacement therapy pellet products and sterile insertion kits, and branded dietary supplements. The platform also includes digital marketing support and point-of-care marketing resources to help practitioners acquire and retain patients.

biote Corp. operates with approximately 217 full-time employees and is headquartered in Irving, Texas. The company maintains a network of certified practitioners across the United States who utilize its platform and products. Founded in 2012, the company is listed on Nasdaq.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2024$0.09$0.09-30.8%
2023$0.13$0.13+208.3%
2022$-0.12$-0.12
2021

Annual Reports (10-K) · 4 filings

Report DateFiledAccession Number
2024-12-312025-03-140000950170-25-039394SEC ↗
2023-12-312024-03-150000950170-24-032101SEC ↗
2022-12-312023-03-290000950170-23-010664SEC ↗
2021-12-312022-04-070001193125-22-097864SEC ↗